Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Leases (2019 - 2025)

Historic Operating Leases for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to $45.2 million.

  • Iovance Biotherapeutics' Operating Leases changed N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $44.4 million for FY2024, which is 3386.75% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Operating Leases stood at $45.2 million.
  • Over the past 5 years, Iovance Biotherapeutics' Operating Leases peaked at $72.3 million during Q1 2024, and registered a low of $44.2 million during Q1 2025.
  • Over the past 3 years, Iovance Biotherapeutics' median Operating Leases value was $67.1 million (recorded in 2023), while the average stood at $58.3 million.
  • Its Operating Leases has fluctuated over the past 5 years, first soared by 384.85% in 2024, then tumbled by 3883.06% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Operating Leases (Quarter) stood at $67.1 million in 2023, then tumbled by 33.87% to $44.4 million in 2024, then grew by 1.91% to $45.2 million in 2025.
  • Its Operating Leases stands at $45.2 million for Q3 2025, versus $45.1 million for Q2 2025 and $44.2 million for Q1 2025.